In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actelion Follows Innovation into GP Markets

Executive Summary

Actelion has become Europe's most successful R&D-based biotech largely on the success of Tracleer for PAH, a specialist indication. Now, facing competition in PAH, but in line with its strategy of following innovation wherever it leads, the company's starting to build a primary care-focused commercial operation to support GP-targeted pipeline assets. That takes Actelion into a very new game, and risks destroying the laissez-faire culture seen as crucial to its unusually high R&D productivity. But Actelion reckons a well-planned, step-wise, and nimble approach to primary care marketing will allow it to retain both the maximum value from its drugs, and its biotech-ness.
Advertisement

Related Content

Approval Delays for J&J/Basilea's Ceftobiprole Shake Partnership
Amgen's D-mab: The New EPO
GSK Tries to Mimic Real-World Biotech
GSK Tries to Mimic Real-World Biotech
GSK/Actelion: Phase III Value Is in the Eye of the Beholder
After Roche/Genentech: Pharma's Focus on Efficiencies, Not Innovation
Can Amgen Find a New Engine?
Co-Promotes: A Marketplace Reality, But Do They Make Sense?
Insomnia: Pharma Wakes Up to the Next Huge CNS Market
Sepracor's Primary Care Ambitions

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003297

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel